{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T01:47:28Z","timestamp":1782092848705,"version":"3.54.5"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82372660"],"award-info":[{"award-number":["82372660"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Key Research and Development Program of China","award":["2023YFB3810004"],"award-info":[{"award-number":["2023YFB3810004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"DOI":"10.1186\/s13046-026-03715-5","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:53:56Z","timestamp":1777870436000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nanocarrier-mediated targeting of NF-\u03baB and JAK\/STAT signaling pathways in hepatocellular carcinoma: mechanisms and therapeutic strategies"],"prefix":"10.1186","volume":"45","author":[{"given":"Muhammad","family":"Azhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"issue":"2","key":"3715_CR1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","volume":"79","author":"H Devarbhavi","year":"2023","unstructured":"Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023;79(2):516\u201337.","journal-title":"J Hepatol"},{"key":"3715_CR2","doi-asserted-by":"crossref","unstructured":"Moawad AW et al. Angiogenesis in hepatocellular carcinoma; pathophysiology, targeted therapy, and role of imaging. J hepatocellular carcinoma, pp. 77\u201389, 2020.","DOI":"10.2147\/JHC.S224471"},{"issue":"Suppl 2","key":"3715_CR3","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s12072-024-10692-4","volume":"18","author":"ME Argenziano","year":"2024","unstructured":"Argenziano ME, et al. Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients. Hep Intl. 2024;18(Suppl 2):922\u201340.","journal-title":"Hep Intl"},{"key":"3715_CR4","doi-asserted-by":"crossref","unstructured":"Lokau J, Schoeder V, Haybaeck J, Garbers C. Jak-stat signaling induced by interleukin-6 family cytokines in hepatocellular carcinoma, Cancers, vol. 11, no. 11, p. 1704, 2019.","DOI":"10.3390\/cancers11111704"},{"issue":"2","key":"3715_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.canlet.2008.12.031","volume":"278","author":"J-M Wu","year":"2009","unstructured":"Wu J-M, et al. NF-\u03baB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. Cancer Lett. 2009;278(2):145\u201355.","journal-title":"Cancer Lett"},{"key":"3715_CR6","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.biopha.2018.03.099","volume":"102","author":"X Lu","year":"2018","unstructured":"Lu X, et al. The anti-inflammatory NHE-06 restores antitumor immunity by targeting NF-\u03baB\/IL-6\/STAT3 signaling in hepatocellular carcinoma. Biomed Pharmacother. 2018;102:420\u20137.","journal-title":"Biomed Pharmacother"},{"key":"3715_CR7","doi-asserted-by":"crossref","unstructured":"Tian K et al. COA6 deficiency inhibits hepatocellular carcinoma progression by regulating cuproptosis through the JAK\/STAT signaling pathway, Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, p. 120065, 2025.","DOI":"10.1016\/j.bbamcr.2025.120065"},{"issue":"1","key":"3715_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12935-025-03728-8","volume":"25","author":"M Sun","year":"2025","unstructured":"Sun M, et al. Exploring the potential mechanisms of sorafenib resistance in hepatocellular carcinoma cell lines based on RNA sequencing. Cancer Cell Int. 2025;25(1):91.","journal-title":"Cancer Cell Int"},{"issue":"5","key":"3715_CR9","doi-asserted-by":"publisher","first-page":"e22722","DOI":"10.1002\/jbt.22722","volume":"35","author":"EI Hassanen","year":"2021","unstructured":"Hassanen EI, Korany RM, Bakeer AM. Cisplatin-conjugated gold nanoparticles\u2010based drug delivery system for targeting hepatic tumors. J Biochem Mol Toxicol. 2021;35(5):e22722.","journal-title":"J Biochem Mol Toxicol"},{"key":"3715_CR10","doi-asserted-by":"crossref","unstructured":"Metkar SP et al. Nanoparticle drug delivery systems in hepatocellular carcinoma: a focus on targeting strategies and therapeutic applications, OpenNano, vol. 12, p. 100159, 2023.","DOI":"10.1016\/j.onano.2023.100159"},{"issue":"13","key":"3715_CR11","doi-asserted-by":"publisher","first-page":"10969","DOI":"10.3390\/ijms241310969","volume":"24","author":"J Krzistetzko","year":"2023","unstructured":"Krzistetzko J, G\u00e9raud C, Dormann C, Riedel A, Leibing T. Association of differentially altered liver fibrosis with deposition of TGFBi in stabilin-deficient mice. Int J Mol Sci. 2023;24(13):10969.","journal-title":"Int J Mol Sci"},{"key":"3715_CR12","doi-asserted-by":"crossref","unstructured":"Buechler C, Aslanidis C. Role of lipids in pathophysiology, diagnosis and therapy of hepatocellular carcinoma, Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, vol. 1865, no. 5, p. 158658, 2020.","DOI":"10.1016\/j.bbalip.2020.158658"},{"issue":"26","key":"3715_CR13","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.3748\/wjg.v27.i26.4104","volume":"27","author":"H Yeh","year":"2021","unstructured":"Yeh H, Chiang C-C, Yen T-H. Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges. World J Gastroenterol. 2021;27(26):4104.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"3715_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11010-024-04983-5","volume":"480","author":"J Jia","year":"2025","unstructured":"Jia J, Zhou X, Chu Q. Mechanisms and therapeutic prospect of the JAK-STAT signaling pathway in liver cancer. Mol Cell Biochem. 2025;480(1):1\u201317.","journal-title":"Mol Cell Biochem"},{"issue":"14","key":"3715_CR15","doi-asserted-by":"publisher","first-page":"11471","DOI":"10.3390\/ijms241411471","volume":"24","author":"M Kotsari","year":"2023","unstructured":"Kotsari M, Dimopoulou V, Koskinas J, Armakolas A. Immune system and hepatocellular carcinoma (HCC): new insights into HCC progression. Int J Mol Sci. 2023;24(14):11471.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3715_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/hepr.12705","volume":"47","author":"T Ikemoto","year":"2017","unstructured":"Ikemoto T, Shimada M, Yamada S. Pathophysiology of recurrent hepatocellular carcinoma after radiofrequency ablation. Hepatol Res. 2017;47(1):23\u201330.","journal-title":"Hepatol Res"},{"key":"3715_CR17","doi-asserted-by":"crossref","unstructured":"Dash S, Chava S, Chandra PK, Aydin Y, Balart LA, Wu T. Autophagy in hepatocellular carcinomas: from pathophysiology to therapeutic response. Hepatic medicine: Evid Res, pp. 9\u201320, 2016.","DOI":"10.2147\/HMER.S63700"},{"issue":"3","key":"3715_CR18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s12072-015-9634-0","volume":"9","author":"H Zou","year":"2015","unstructured":"Zou H, Feng X, Cao J-G. Twist in hepatocellular carcinoma: pathophysiology and therapeutics. Hep Intl. 2015;9(3):399\u2013405.","journal-title":"Hep Intl"},{"issue":"2","key":"3715_CR19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrgastro.2010.213","volume":"8","author":"T Luedde","year":"2011","unstructured":"Luedde T, Schwabe RF. NF-\u03baB in the liver\u2014linking injury, fibrosis and hepatocellular carcinoma. Nat reviews Gastroenterol Hepatol. 2011;8(2):108\u201318.","journal-title":"Nat reviews Gastroenterol Hepatol"},{"issue":"1","key":"3715_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1476-4598-13-35","volume":"13","author":"N Zhao","year":"2014","unstructured":"Zhao N, Wang R, Zhou L, Zhu Y, Gong J, Zhuang S-M. MicroRNA-26b suppresses the NF-\u03baB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and Table 3. Mol Cancer. 2014;13(1):35.","journal-title":"Mol Cancer"},{"issue":"6","key":"3715_CR21","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s13402-016-0294-4","volume":"39","author":"V Ramesh","year":"2016","unstructured":"Ramesh V, Selvarasu K, Pandian J, Myilsamy S, Shanmugasundaram C, Ganesan K. NF\u03baB activation demarcates a subset of hepatocellular carcinoma patients for targeted therapy. Cell Oncol. 2016;39(6):523\u201336.","journal-title":"Cell Oncol"},{"issue":"05","key":"3715_CR22","first-page":"747","volume":"116","author":"J Wang","year":"2003","unstructured":"Wang J, Huang Q, Chen M. The role of NF-\u03baB in hepatocellular carcinoma cell. Chin Med J. 2003;116(05):747\u201352.","journal-title":"Chin Med J"},{"key":"3715_CR23","doi-asserted-by":"crossref","unstructured":"Jia X, Wei S, Xiong W. CXCL5\/NF-\u03baB pathway as a therapeutic target in hepatocellular carcinoma treatment, Journal of oncology, vol. 2021, no. 1, p. 9919494, 2021.","DOI":"10.1155\/2021\/9919494"},{"key":"3715_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.biocel.2017.05.031","volume":"89","author":"W Dai","year":"2017","unstructured":"Dai W, et al. Genes directly regulated by NF-\u03baB in human hepatocellular carcinoma HepG2. Int J Biochem Cell Biol. 2017;89:157\u201370.","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"3715_CR25","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s13046-021-02062-x","volume":"40","author":"X Xu","year":"2021","unstructured":"Xu X, et al. Phosphorylation of NF-\u03baBp65 drives inflammation-mediated hepatocellular carcinogenesis and is a novel therapeutic target. J Experimental Clin Cancer Res. 2021;40(1):253.","journal-title":"J Experimental Clin Cancer Res"},{"issue":"3","key":"3715_CR26","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1089\/hum.2006.17.280","volume":"17","author":"L Qiao","year":"2006","unstructured":"Qiao L, et al. Constitutive activation of NF-\u03baB in human hepatocellular carcinoma: evidence of a cytoprotective role. Hum Gene Ther. 2006;17(3):280\u201390.","journal-title":"Hum Gene Ther"},{"issue":"6","key":"3715_CR27","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3349\/ymj.2020.61.6.460","volume":"61","author":"X Fei","year":"2020","unstructured":"Fei X, Zhang P, Pan Y, Liu Y. MicroRNA-98-5p inhibits tumorigenesis of hepatitis B virus-related hepatocellular carcinoma by targeting NF-\u03baB-inducing kinase. Yonsei Med J. 2020;61(6):460.","journal-title":"Yonsei Med J"},{"issue":"3","key":"3715_CR28","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.bbrc.2014.12.119","volume":"457","author":"L Zhao","year":"2015","unstructured":"Zhao L, Zhang Y. miR-342-3p affects hepatocellular carcinoma cell proliferation via regulating NF-\u03baB pathway. Biochem Biophys Res Commun. 2015;457(3):370\u20137.","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"3715_CR29","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1158\/1078-0432.CCR-15-0780","volume":"22","author":"T-J Wu","year":"2016","unstructured":"Wu T-J, et al. Severe Hepatitis Promotes Hepatocellular Carcinoma Recurrence via NF-\u03baB Pathway-Mediated Epithelial\u2013Mesenchymal Transition after Resection. Clin Cancer Res. 2016;22(7):1800\u201312.","journal-title":"Clin Cancer Res"},{"key":"3715_CR30","doi-asserted-by":"publisher","first-page":"116566","DOI":"10.1016\/j.biopha.2024.116566","volume":"174","author":"S Wang","year":"2024","unstructured":"Wang S, He Y, Wang J, Luo E. Re-exploration of immunotherapy targeting EMT of hepatocellular carcinoma: Starting from the NF-\u03baB pathway. Biomed Pharmacother. 2024;174:116566.","journal-title":"Biomed Pharmacother"},{"key":"3715_CR31","doi-asserted-by":"publisher","first-page":"121715","DOI":"10.1016\/j.lfs.2023.121715","volume":"324","author":"J-P Lin","year":"2023","unstructured":"Lin J-P, et al. Periplocin inhibits hepatocellular carcinoma progression and reduces the recruitment of MDSCs through AKT\/NF-\u03baB pathway. Life Sci. 2023;324:121715.","journal-title":"Life Sci"},{"key":"3715_CR32","doi-asserted-by":"crossref","unstructured":"Zhang N et al. Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-\u03baB signaling pathway, Oncotarget, vol. 5, no. 18, p. 8330, 2014.","DOI":"10.18632\/oncotarget.2212"},{"key":"3715_CR33","doi-asserted-by":"crossref","unstructured":"Chen JC-H, Chuang H-Y, Hsu F-T, Chen Y-C, Chien Y-C, Hwang J-J. Sorafenib pretreatment enhances radiotherapy through targeting MEK\/ERK\/NF-\u03baB pathway in human hepatocellular carcinoma-bearing mouse model, Oncotarget, vol. 7, no. 51, p. 85450, 2016.","DOI":"10.18632\/oncotarget.13398"},{"issue":"9","key":"3715_CR34","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/bjc.2015.272","volume":"113","author":"K Shinoda","year":"2015","unstructured":"Shinoda K, et al. Pin1 facilitates NF-\u03baB activation and promotes tumour progression in human hepatocellular carcinoma. Br J Cancer. 2015;113(9):1323\u201331.","journal-title":"Br J Cancer"},{"key":"3715_CR35","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ebiom.2019.06.048","volume":"45","author":"T Wang","year":"2019","unstructured":"Wang T, et al. Aspirin targets P4HA2 through inhibiting NF-\u03baB and LMCD1-AS1\/let-7\u00a0g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma. EBioMedicine. 2019;45:168\u201380.","journal-title":"EBioMedicine"},{"issue":"1","key":"3715_CR36","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1186\/s12885-019-6312-y","volume":"19","author":"Z-T Shen","year":"2019","unstructured":"Shen Z-T, Chen Y, Huang G-C, Zhu X-X, Wang R, Chen L-B. Aurora-a confers radioresistance in human hepatocellular carcinoma by activating NF-\u03baB signaling pathway. BMC Cancer. 2019;19(1):1075.","journal-title":"BMC Cancer"},{"issue":"1","key":"3715_CR37","doi-asserted-by":"publisher","first-page":"26422","DOI":"10.1038\/s41598-024-78316-3","volume":"14","author":"Q-b Zhang","year":"2024","unstructured":"Zhang Q-b, et al. TLR3 activation enhances antitumor effects of sorafenib in hepatocellular carcinoma by activating NK cell functions through ERK and NF-\u03baB pathways. Sci Rep. 2024;14(1):26422.","journal-title":"Sci Rep"},{"key":"3715_CR38","doi-asserted-by":"publisher","first-page":"760971","DOI":"10.3389\/fonc.2021.760971","volume":"11","author":"J Xu","year":"2021","unstructured":"Xu J, Lin H, Wu G, Zhu M, Li M. IL-6\/STAT3 is a promising therapeutic target for hepatocellular carcinoma. Front Oncol. 2021;11:760971.","journal-title":"Front Oncol"},{"issue":"1","key":"3715_CR39","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jhep.2019.08.035","volume":"72","author":"TB Toh","year":"2020","unstructured":"Toh TB, Lim JJ, Hooi L, Rashid MBMA, Chow EK-H. Targeting Jak\/Stat pathway as a therapeutic strategy against SP\/CD44\u2009+\u2009tumorigenic cells in Akt\/\u03b2-catenin-driven hepatocellular carcinoma. J Hepatol. 2020;72(1):104\u201318.","journal-title":"J Hepatol"},{"key":"3715_CR40","doi-asserted-by":"crossref","unstructured":"Villanueva A et al. Pivotal role of mTOR signaling in hepatocellular carcinoma, Gastroenterology, vol. 135, no. 6, pp. 1972\u20131983. e11, 2008.","DOI":"10.1053\/j.gastro.2008.08.008"},{"issue":"18","key":"3715_CR41","doi-asserted-by":"publisher","first-page":"13764","DOI":"10.3390\/ijms241813764","volume":"24","author":"H Park","year":"2023","unstructured":"Park H, Lee S, Lee J, Moon H, Ro SW. Exploring the JAK\/STAT signaling pathway in hepatocellular carcinoma: unraveling signaling complexity and therapeutic implications. Int J Mol Sci. 2023;24(18):13764.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"3715_CR42","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1007\/s10238-023-01047-8","volume":"23","author":"B Rah","year":"2023","unstructured":"Rah B, Farhat NM, Hamad M, Muhammad JS. JAK\/STAT signaling and cellular iron metabolism in hepatocellular carcinoma: therapeutic implications. Clin Experimental Med. 2023;23(7):3147\u201357.","journal-title":"Clin Experimental Med"},{"key":"3715_CR43","doi-asserted-by":"crossref","unstructured":"Yang S et al. Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma, Oncotarget, vol. 7, no. 5, p. 5461, 2015.","DOI":"10.18632\/oncotarget.6684"},{"issue":"5","key":"3715_CR44","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41419-019-1530-4","volume":"10","author":"W Ren","year":"2019","unstructured":"Ren W, Wu S, Wu Y, Liu T, Zhao X, Li Y. MicroRNA-196a\/-196b regulate the progression of hepatocellular carcinoma through modulating the JAK\/STAT pathway via targeting SOCS2. Cell Death Dis. 2019;10(5):333.","journal-title":"Cell Death Dis"},{"key":"3715_CR45","doi-asserted-by":"crossref","unstructured":"Calvisi DF et al. Ubiquitous activation of Ras and Jak\/Stat pathways in human HCC, Gastroenterology, vol. 130, no. 4, pp. 1117\u20131128, 2006.","DOI":"10.1053\/j.gastro.2006.01.006"},{"issue":"4","key":"3715_CR46","first-page":"805","volume":"55","author":"X Wang","year":"2019","unstructured":"Wang X, et al. Analysis of clinical significance and prospective molecular mechanism of main elements of the JAK\/STAT pathway in hepatocellular carcinoma. Int J Oncol. 2019;55(4):805\u201322.","journal-title":"Int J Oncol"},{"key":"3715_CR47","doi-asserted-by":"publisher","first-page":"104868","DOI":"10.1016\/j.phrs.2020.104868","volume":"158","author":"M Zhu","year":"2020","unstructured":"Zhu M, et al. Cantharidin treatment inhibits hepatocellular carcinoma development by regulating the JAK2\/STAT3 and PI3K\/Akt pathways in an EphB4-dependent manner. Pharmacol Res. 2020;158:104868.","journal-title":"Pharmacol Res"},{"key":"3715_CR48","doi-asserted-by":"crossref","unstructured":"Cherng Y-G et al. Induced mitochondrial alteration and DNA damage via IFNGR-JAK2-STAT1-PARP1 pathway facilitates viral hepatitis associated hepatocellular carcinoma aggressiveness and stemness, Cancers, vol. 13, no. 11, p. 2755, 2021.","DOI":"10.3390\/cancers13112755"},{"issue":"7","key":"3715_CR49","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41419-020-02807-0","volume":"11","author":"L Yang","year":"2020","unstructured":"Yang L, Xue H, Sun Y, Zhang L, Xue F, Ge R. CircularRNA-9119 protects hepatocellular carcinoma cells from apoptosis by intercepting miR-26a\/JAK1\/STAT3 signaling. Cell Death Dis. 2020;11(7):605.","journal-title":"Cell Death Dis"},{"issue":"3","key":"3715_CR50","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.bbamcr.2005.06.003","volume":"1745","author":"K Inamura","year":"2005","unstructured":"Inamura K, Matsuzaki Y, Uematsu N, Honda A, Tanaka N, Uchida K. Rapid inhibition of MAPK signaling and anti-proliferation effect via JAK\/STAT signaling by interferon-\u03b1 in hepatocellular carcinoma cell lines. Biochim et Biophys Acta (BBA)-Molecular Cell Res. 2005;1745(3):401\u201310.","journal-title":"Biochim et Biophys Acta (BBA)-Molecular Cell Res"},{"key":"3715_CR51","doi-asserted-by":"crossref","unstructured":"Xu B et al. EPHX1 enhances drug resistance to regorafenib by activating the JAK\/STAT signaling pathway in hepatocellular carcinoma cell lines, Hereditas, vol. 162, no. 1, p. 148, 2025.","DOI":"10.1186\/s41065-025-00517-1"},{"issue":"2","key":"3715_CR52","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.canlet.2013.08.009","volume":"341","author":"GS Wilson","year":"2013","unstructured":"Wilson GS, et al. Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro. Cancer Lett. 2013;341(2):224\u201330.","journal-title":"Cancer Lett"},{"key":"3715_CR53","doi-asserted-by":"crossref","unstructured":"Igbe I et al. Dietary quercetin potentiates the antiproliferative effect of interferon-\u03b1 in hepatocellular carcinoma cells through activation of JAK\/STAT pathway signaling by inhibition of SHP2 phosphatase, Oncotarget, vol. 8, no. 69, p. 113734, 2017.","DOI":"10.18632\/oncotarget.22556"},{"issue":"1","key":"3715_CR54","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12943-021-01377-9","volume":"20","author":"Z-K Liu","year":"2021","unstructured":"Liu Z-K, et al. EYA2 suppresses the progression of hepatocellular carcinoma via SOCS3-mediated blockade of JAK\/STAT signaling. Mol Cancer. 2021;20(1):79.","journal-title":"Mol Cancer"},{"issue":"5","key":"3715_CR55","doi-asserted-by":"publisher","first-page":"379","DOI":"10.5847\/wjem.j.1920-8642.2022.089","volume":"13","author":"X-h Zhou","year":"2022","unstructured":"Zhou X-h, et al. Hepatocellular carcinoma-derived exosomal miRNA-761 regulates the tumor microenvironment by targeting the SOCS2\/JAK2\/STAT3 pathway. World J Emerg Med. 2022;13(5):379.","journal-title":"World J Emerg Med"},{"key":"3715_CR56","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.biopha.2016.04.061","volume":"82","author":"M Ilamathi","year":"2016","unstructured":"Ilamathi M, Prabu P, Ayyappa KA, Sivaramakrishnan V. Artesunate obliterates experimental hepatocellular carcinoma in rats through suppression of IL-6-JAK-STAT signalling. Biomed Pharmacother. 2016;82:72\u20139.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"3715_CR57","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/cr.2010.183","volume":"21","author":"G He","year":"2011","unstructured":"He G, Karin M. NF-\u03baB and STAT3\u2013key players in liver inflammation and cancer. Cell Res. 2011;21(1):159\u201368.","journal-title":"Cell Res"},{"issue":"31","key":"3715_CR58","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.3748\/wjg.v18.i31.4071","volume":"18","author":"H Nakagawa","year":"2012","unstructured":"Nakagawa H, Maeda S. Inflammation-and stress-related signaling pathways in hepatocarcinogenesis. World J gastroenterology: WJG. 2012;18(31):4071.","journal-title":"World J gastroenterology: WJG"},{"issue":"1","key":"3715_CR59","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s11658-023-00438-9","volume":"28","author":"M Hashemi","year":"2023","unstructured":"Hashemi M, et al. Deciphering STAT3 signaling potential in hepatocellular carcinoma: tumorigenesis, treatment resistance, and pharmacological significance. Cell Mol Biol Lett. 2023;28(1):33.","journal-title":"Cell Mol Biol Lett"},{"issue":"1","key":"3715_CR60","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.yexcr.2015.07.007","volume":"337","author":"P Xu","year":"2015","unstructured":"Xu P, Sun Z, Miao C. Long-term use of indomethacin leads to poor prognoses through promoting the expression of PD-1 and PD-L2 via TRIF\/NF-\u03baB pathway and JAK\/STAT3 pathway to inhibit TNF-\u03b1 and IFN-\u03b3 in hepatocellular carcinoma. Exp Cell Res. 2015;337(1):53\u201360.","journal-title":"Exp Cell Res"},{"issue":"3","key":"3715_CR61","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ccr.2009.12.048","volume":"17","author":"G He","year":"2010","unstructured":"He G, et al. Hepatocyte IKK\u03b2\/NF-\u03baB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell. 2010;17(3):286\u201397.","journal-title":"Cancer Cell"},{"key":"3715_CR62","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cancergen.2020.04.076","volume":"245","author":"H Lin","year":"2020","unstructured":"Lin H, Zhang R, Wu W, Lei L. Comprehensive network analysis of the molecular mechanisms associated with sorafenib resistance in hepatocellular carcinoma. Cancer Genet. 2020;245:27\u201334.","journal-title":"Cancer Genet"},{"issue":"5","key":"3715_CR63","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1158\/0008-5472.CAN-20-2480","volume":"81","author":"Q Zhou","year":"2021","unstructured":"Zhou Q, et al. A positive feedback loop of AKR1C3-mediated activation of NF-\u03baB and STAT3 facilitates proliferation and metastasis in hepatocellular carcinoma. Cancer Res. 2021;81(5):1361\u201374.","journal-title":"Cancer Res"},{"issue":"1","key":"3715_CR64","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s44337-025-00441-3","volume":"2","author":"X Wang","year":"2025","unstructured":"Wang X, Zhang L, Ma W-L, Ma Z-m, Ma L-N, Ding X-C. Inflammatory mechanisms mediated by C-reactive protein in hepatitis B virus replication and hepatocellular carcinoma progression. Discover Med. 2025;2(1):203.","journal-title":"Discover Med"},{"key":"3715_CR65","doi-asserted-by":"crossref","unstructured":"Kong F-H et al. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma, Theranostics, vol. 11, no. 11, p. 5464, 2021.","DOI":"10.7150\/thno.54822"},{"issue":"5","key":"3715_CR66","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1080\/1061186X.2024.2344495","volume":"32","author":"R Zou","year":"2024","unstructured":"Zou R, et al. Trimethyl chitosan\u2013cysteine-based nanoparticles as an effective delivery system for portulacerebroside A in the management of hepatocellular carcinoma cells in vitro and in vivo. J Drug Target. 2024;32(5):570\u201384.","journal-title":"J Drug Target"},{"key":"3715_CR67","doi-asserted-by":"crossref","unstructured":"Tang B et al. Upregulation of Akt\/NF-\u03baB-regulated inflammation and Akt\/Bad-related apoptosis signaling pathway involved in hepatic carcinoma process: suppression by carnosic acid nanoparticle. Int J Nanomed, pp. 6401\u201320, 2016.","DOI":"10.2147\/IJN.S101285"},{"issue":"1","key":"3715_CR68","doi-asserted-by":"publisher","first-page":"15538","DOI":"10.1038\/s41598-024-65235-6","volume":"14","author":"DS Khafaga","year":"2024","unstructured":"Khafaga DS, et al. Enhanced anticancer activity of silver doped zinc oxide magnetic nanocarrier loaded with sorafenib for hepatocellular carcinoma treatment. Sci Rep. 2024;14(1):15538.","journal-title":"Sci Rep"},{"issue":"1","key":"3715_CR69","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.nano.2018.09.002","volume":"15","author":"Y-Q Zhang","year":"2019","unstructured":"Zhang Y-Q, et al. Galactosylated chitosan triptolide nanoparticles for overcoming hepatocellular carcinoma: enhanced therapeutic efficacy, low toxicity, and validated network regulatory mechanisms. Nanomed Nanotechnol Biol Med. 2019;15(1):86\u201397.","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"3715_CR70","doi-asserted-by":"crossref","unstructured":"Tang H et al. Effect of inhibitors of endocytosis and NF-kB signal pathway on folate-conjugated nanoparticle endocytosis by rat Kupffer cells. Int J Nanomed, pp. 6937\u201347, 2017.","DOI":"10.2147\/IJN.S141407"},{"issue":"3","key":"3715_CR71","doi-asserted-by":"publisher","first-page":"BSR20171264","DOI":"10.1042\/BSR20171264","volume":"38","author":"M-C Weng","year":"2018","unstructured":"Weng M-C, et al. Regorafenib inhibits tumor progression through suppression of ERK\/NF-\u03baB activation in hepatocellular carcinoma bearing mice. Biosci Rep. 2018;38(3):BSR20171264.","journal-title":"Biosci Rep"},{"issue":"6","key":"3715_CR72","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1049\/iet-nbt.2020.0002","volume":"14","author":"P Wang","year":"2020","unstructured":"Wang P, Shen Y, Zhao L. Chitosan nanoparticles loaded with aspirin and 5-fluororacil enable synergistic antitumour activity through the modulation of NF\u2010\u03baB\/COX\u20102 signalling pathway. IET Nanobiotechnol. 2020;14(6):479\u201384.","journal-title":"IET Nanobiotechnol"},{"issue":"7","key":"3715_CR73","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1039\/D2FO02191A","volume":"14","author":"G-l Li","year":"2023","unstructured":"Li G-l, et al. The anti-hepatocellular carcinoma effects of polysaccharides from Ganoderma lucidum by regulating macrophage polarization via the MAPK\/NF-\u03baB signaling pathway. Food Funct. 2023;14(7):3155\u201368.","journal-title":"Food Funct"},{"issue":"8","key":"3715_CR74","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1038\/s41401-023-01062-1","volume":"44","author":"Y-f Wang","year":"2023","unstructured":"Wang Y-f, et al. Aspirin triggers ferroptosis in hepatocellular carcinoma cells through restricting NF-\u03baB p65-activated SLC7A11 transcription. Acta Pharmacol Sin. 2023;44(8):1712\u201324.","journal-title":"Acta Pharmacol Sin"},{"key":"3715_CR75","doi-asserted-by":"crossref","unstructured":"Pandey P et al. Implication of nano-antioxidant therapy for treatment of hepatocellular carcinoma using PLGA nanoparticles of rutin, Nanomedicine, vol. 13, no. 8, pp. 849\u2013870, 2018.","DOI":"10.2217\/nnm-2017-0306"},{"issue":"1","key":"3715_CR76","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s13046-018-1005-y","volume":"37","author":"Y Qiu","year":"2018","unstructured":"Qiu Y, et al. Arsenic trioxide reverses the chemoresistance in hepatocellular carcinoma: a targeted intervention of 14-3-3\u03b7\/NF-\u03baB feedback loop. J Experimental Clin Cancer Res. 2018;37(1):321.","journal-title":"J Experimental Clin Cancer Res"},{"issue":"30","key":"3715_CR77","doi-asserted-by":"publisher","first-page":"26731","DOI":"10.1021\/acsami.9b10164","volume":"11","author":"MA Abdelmoneem","year":"2019","unstructured":"Abdelmoneem MA, et al. Dual-targeted lactoferrin shell-oily core nanocapsules for synergistic targeted\/herbal therapy of hepatocellular carcinoma. ACS Appl Mater Interfaces. 2019;11(30):26731\u201344.","journal-title":"ACS Appl Mater Interfaces"},{"key":"3715_CR78","doi-asserted-by":"crossref","unstructured":"Xiong X et al. Selective killing of hepatocellular carcinoma HepG2 cells by three-dimensional nanographene nanoparticles based on triptycene, Nanoscale, vol. 7, no. 12, pp. 5217\u20135229, 2015.","DOI":"10.1039\/C4NR07248K"},{"issue":"2","key":"3715_CR79","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3892\/br.2024.1907","volume":"22","author":"T Batsukh","year":"2024","unstructured":"Batsukh T, Tsend-Ayush A. Herbal drug\u2013based nanotherapy for hepatocellular carcinoma: Quercetin\u2013contained nanocarrier as a multipurpose therapeutic agent against hepatocellular carcinoma. Biomedical Rep. 2024;22(2):29.","journal-title":"Biomedical Rep"},{"issue":"1","key":"3715_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11033-025-11011-2","volume":"52","author":"RF Alzahrani","year":"2025","unstructured":"Alzahrani RF, et al. Folate-and chitosan-functionalized lipid nanoparticles for co-delivery of pioglitazone and simvastatin to enhance hepatic cancer therapy: effects on IL-1\u03b2, IL-6, BCL2\/BAX gene expression, and GPX4, COX-2, and MMP-9 activities. Mol Biol Rep. 2025;52(1):1\u201322.","journal-title":"Mol Biol Rep"},{"issue":"8","key":"3715_CR81","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41401-024-01261-4","volume":"45","author":"Q-y Zhang","year":"2024","unstructured":"Zhang Q-y, et al. Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma. Acta Pharmacol Sin. 2024;45(8):1701\u201314.","journal-title":"Acta Pharmacol Sin"},{"key":"3715_CR82","doi-asserted-by":"crossref","unstructured":"Raghav A, Jeong GB. Nanoquercetin and extracellular vesicles as potential anticancer therapeutics in hepatocellular carcinoma, Cells, vol. 13, no. 7, p. 638, 2024.","DOI":"10.3390\/cells13070638"},{"issue":"1","key":"3715_CR83","doi-asserted-by":"publisher","first-page":"20221018","DOI":"10.1515\/biol-2022-1018","volume":"20","author":"G Wang","year":"2025","unstructured":"Wang G, Zhu Z, Sun Z, Yang Z. Mechanism of triptolide regulating proliferation and apoptosis of hepatoma cells by inhibiting JAK\/STAT pathway. Open Life Sci. 2025;20(1):20221018.","journal-title":"Open Life Sci"},{"key":"3715_CR84","doi-asserted-by":"crossref","unstructured":"Thalij KM, You HW, Aher KB, Bhavar GB, Kumbhar ST, Habeeb M. Advances in Lipid-Based Nanomedicine: Pathway Specific siRNA Therapy and Optimizing Delivery for Hepatocellular Carcinoma. Int J Nanomed, pp. 10541\u201366, 2025.","DOI":"10.2147\/IJN.S532246"},{"issue":"3","key":"3715_CR85","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1093\/toxres\/tfab018","volume":"10","author":"Q Xu","year":"2021","unstructured":"Xu Q, et al. Promotion effects of DEHP on hepatocellular carcinoma models: up-regulation of PD-L1 by activating the JAK2\/STAT3 pathway. Toxicol Res. 2021;10(3):376\u201388.","journal-title":"Toxicol Res"},{"key":"3715_CR86","doi-asserted-by":"publisher","first-page":"109261","DOI":"10.1016\/j.steroids.2023.109261","volume":"198","author":"MM \u00dcremi\u015f","year":"2023","unstructured":"\u00dcremi\u015f MM, \u00dcremi\u015f N, T\u00fcrk\u00f6z Y. Cucurbitacin E shows synergistic effect with sorafenib by inducing apoptosis in hepatocellular carcinoma cells and regulates Jak\/Stat3, ERK\/MAPK, PI3K\/Akt\/mTOR signaling pathways. Steroids. 2023;198:109261.","journal-title":"Steroids"},{"key":"3715_CR87","doi-asserted-by":"crossref","unstructured":"Wang F et al. Silencing PTPN2 with nanoparticle-delivered small interfering RNA remodels tumor microenvironment to sensitize immunotherapy in hepatocellular carcinoma. Acta Pharm Sinica B, 2025.","DOI":"10.1016\/j.apsb.2025.03.015"},{"issue":"5","key":"3715_CR88","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1134\/S002689332570030X","volume":"59","author":"X Li","year":"2025","unstructured":"Li X, et al. IFN\u03b3 Upregulating miR-1291 Promotes Cell Proliferation and Enhances Phosphorylation of the JAK\/STAT Signaling Pathway by Targeting SOCS3 in HepG2 Cells. Mol Biol. 2025;59(5):729\u201347.","journal-title":"Mol Biol"},{"key":"3715_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2018.05.007","volume":"545","author":"Y Cheng","year":"2018","unstructured":"Cheng Y, et al. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma. Int J Pharm. 2018;545:1\u20132.","journal-title":"Int J Pharm"},{"issue":"1","key":"3715_CR90","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/21691401.2023.2238756","volume":"51","author":"S Harakeh","year":"2023","unstructured":"Harakeh S, et al. Novel curcumin nanoformulation induces apoptosis, and reduces migration and angiogenesis in liver cancer cells. Artif cells Nanomed Biotechnol. 2023;51(1):361\u201370.","journal-title":"Artif cells Nanomed Biotechnol"},{"key":"3715_CR91","doi-asserted-by":"publisher","first-page":"961788","DOI":"10.3389\/fphar.2022.961788","volume":"13","author":"J Wu","year":"2022","unstructured":"Wu J, et al. Curcumin and berberine co-loaded liposomes for anti-hepatocellular carcinoma therapy by blocking the cross-talk between hepatic stellate cells and tumor cells. Front Pharmacol. 2022;13:961788.","journal-title":"Front Pharmacol"},{"key":"3715_CR92","doi-asserted-by":"crossref","unstructured":"Li X-D et al. Berberine-loaded Janus gold mesoporous silica nanocarriers for chemo\/radio\/photothermal therapy of liver cancer and radiation-induced injury inhibition. Int J Nanomed, pp. 3967\u201382, 2019.","DOI":"10.2147\/IJN.S206044"},{"issue":"70","key":"3715_CR93","doi-asserted-by":"publisher","first-page":"40288","DOI":"10.1039\/C8RA07574C","volume":"8","author":"J Yue","year":"2018","unstructured":"Yue J, et al. Cancer cell membrane-modified biodegradable mesoporous silica nanocarriers for berberine therapy of liver cancer. RSC Adv. 2018;8(70):40288\u201397.","journal-title":"RSC Adv"},{"issue":"1","key":"3715_CR94","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1080\/10717544.2019.1606865","volume":"26","author":"M Rahman","year":"2019","unstructured":"Rahman M, et al. Ganoderic acid loaded nano-lipidic carriers improvise treatment of hepatocellular carcinoma. Drug Delivery. 2019;26(1):782\u201393.","journal-title":"Drug Delivery"},{"key":"3715_CR95","doi-asserted-by":"crossref","unstructured":"Yousef S, Alsaab HO, Sau S, Iyer AK. Development of asialoglycoprotein receptor directed nanoparticles for selective delivery of curcumin derivative to hepatocellular carcinoma, Heliyon, vol. 4, no. 12, 2018.","DOI":"10.1016\/j.heliyon.2018.e01071"},{"issue":"4","key":"3715_CR96","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s43450-024-00538-3","volume":"34","author":"SM Shabana","year":"2024","unstructured":"Shabana SM, et al. Encapsulating Epigallocatechin-3-Gallate (EGCG) in Chitosan nanoparticles influenced multiple genes controlling oncostatic signaling pathways in HepG2 cells. Revista Brasileira De Farmacognosia. 2024;34(4):831\u201342.","journal-title":"Revista Brasileira De Farmacognosia"},{"key":"3715_CR97","doi-asserted-by":"crossref","unstructured":"Rodponthukwaji K et al. Epigallocatechin gallate potentiates the anticancer effect of AFP-siRNA-loaded polymeric nanoparticles on hepatocellular carcinoma cells, Nanomaterials, vol. 14, no. 1, p. 47, 2023.","DOI":"10.3390\/nano14010047"},{"key":"3715_CR98","doi-asserted-by":"publisher","first-page":"1673134","DOI":"10.3389\/fbioe.2025.1673134","volume":"13","author":"X Liao","year":"2025","unstructured":"Liao X, et al. Responsive biomaterials for therapeutic strategies of hepatocellular carcinoma. Front Bioeng Biotechnol. 2025;13:1673134.","journal-title":"Front Bioeng Biotechnol"},{"key":"3715_CR99","doi-asserted-by":"publisher","first-page":"100338","DOI":"10.1016\/j.mtbio.2022.100338","volume":"16","author":"T Chen","year":"2022","unstructured":"Chen T, et al. A multi-hit therapeutic nanoplatform for hepatocellular carcinoma: dual stimuli-responsive drug release, dual-modal imaging, and in situ oxygen supply to enhance synergistic therapy. Mater Today Bio. 2022;16:100338.","journal-title":"Mater Today Bio"},{"key":"3715_CR100","doi-asserted-by":"crossref","unstructured":"Ta Y-NN et al. Stimuli-Responsive Nanozyme Reprograms Tumor Immunometabolism and Overcomes Therapeutic Resistance in Hepatocellular Carcinoma. ACS Nano, 2026.","DOI":"10.1021\/acsnano.5c11352"},{"key":"3715_CR101","doi-asserted-by":"crossref","unstructured":"Song L et al. ROS-responsive nanosystem targeted co-delivery YC-1 and regorafenib to alleviate hypoxia enhancing hepatocellular carcinoma therapy. Int J Nanomed pp. 8481\u201396, 2025.","DOI":"10.2147\/IJN.S518120"},{"key":"3715_CR102","doi-asserted-by":"publisher","first-page":"100902","DOI":"10.1016\/j.mtbio.2023.100902","volume":"24","author":"W Xu","year":"2024","unstructured":"Xu W, Yang M, Zhang W, Jia W, Zhang H, Zhang Y. Tumor microenvironment responsive nano-platform for overcoming sorafenib resistance of hepatocellular carcinoma. Mater Today Bio. 2024;24:100902.","journal-title":"Mater Today Bio"},{"key":"3715_CR103","doi-asserted-by":"crossref","unstructured":"Ruman U, Fakurazi S, Masarudin MJ, Hussein MZ. Nanocarrier-based therapeutics and theranostics drug delivery systems for next generation of liver cancer nanodrug modalities. Int J Nanomed, pp. 1437\u201356, 2020.","DOI":"10.2147\/IJN.S236927"},{"key":"3715_CR104","doi-asserted-by":"crossref","unstructured":"Nag S, Ong YS, Narayanan K, Subramaniyan V, Naidu R. Mechanistic Insights into Nanomaterials and Advanced Drug Delivery Platforms for the Theranostic Management of Hepatic Cancer: A Comprehensive Update, BioNanoScience, 15, 4, p. 587, 2025.","DOI":"10.1007\/s12668-025-02175-z"},{"key":"3715_CR105","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.biomaterials.2018.07.060","volume":"181","author":"L Zhang","year":"2018","unstructured":"Zhang L, et al. Dual drug delivery and sequential release by amphiphilic Janus nanoparticles for liver cancer theranostics. Biomaterials. 2018;181:113\u201325.","journal-title":"Biomaterials"},{"key":"3715_CR106","doi-asserted-by":"crossref","unstructured":"Bonferoni MC, Gavini E, Rassu G, Maestri M, Giunchedi P. Chitosan nanoparticles for therapy and theranostics of hepatocellular carcinoma (HCC) and liver-targeting, Nanomaterials, vol. 10, no. 5, p. 870, 2020.","DOI":"10.3390\/nano10050870"},{"issue":"12","key":"3715_CR107","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1039\/D0BM00295J","volume":"8","author":"M Cai","year":"2020","unstructured":"Cai M, et al. A reduction and pH dual-sensitive nanodrug for targeted theranostics in hepatocellular carcinoma. Biomaterials Sci. 2020;8(12):3485\u201399.","journal-title":"Biomaterials Sci"},{"issue":"3","key":"3715_CR108","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1166\/jbn.2022.3297","volume":"18","author":"T Tian","year":"2022","unstructured":"Tian T, Ruan J, Zhang J, Zhao C-X, Chen D, Shan J. Nanocarrier-based tumor-targeting drug delivery systems for hepatocellular carcinoma treatments: Enhanced therapeutic efficacy and reduced drug toxicity. J Biomed Nanotechnol. 2022;18(3):660\u201376.","journal-title":"J Biomed Nanotechnol"},{"issue":"4","key":"3715_CR109","doi-asserted-by":"publisher","first-page":"e000238","DOI":"10.1136\/esmoopen-2017-000238","volume":"2","author":"P Merle","year":"2017","unstructured":"Merle P, et al. Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinoma. ESMO open. 2017;2(4):e000238.","journal-title":"ESMO open"},{"key":"3715_CR110","doi-asserted-by":"publisher","first-page":"124815","DOI":"10.1016\/j.ijpharm.2024.124815","volume":"667","author":"F Delaporte","year":"2024","unstructured":"Delaporte F, Roger E, Bejaud J, Loyer P, Lagarce F, Savary CC. Internalization and mechanisms of toxicity of lipid nanocapsules in HepG2 and HepaRG hepatoma cells upon acute and chronic exposures. Int J Pharm. 2024;667:124815.","journal-title":"Int J Pharm"},{"key":"3715_CR111","doi-asserted-by":"crossref","unstructured":"Skorzynski M, Krol M, Braniewska A. Hepatotoxicity of nanoparticle-based anti-cancer drugs: insights into toxicity and mitigation strategies. Int J Nanomed, pp. 11697\u2013715, 2025.","DOI":"10.2147\/IJN.S543433"},{"key":"3715_CR112","doi-asserted-by":"crossref","unstructured":"Jackson MA et al. Kupffer cell release of platelet activating factor drives dose limiting toxicities of nucleic acid nanocarriers, Biomaterials, vol. 268, p. 120528, 2021.","DOI":"10.1016\/j.biomaterials.2020.120528"},{"issue":"10","key":"3715_CR113","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/jnci\/djn134","volume":"100","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(10):698\u2013711.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"3715_CR114","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.nano.2009.01.009","volume":"5","author":"Q Zhou","year":"2009","unstructured":"Zhou Q, Sun X, Zeng L, Liu J, Zhang Z. A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma. Nanomed Nanotechnol Biol Med. 2009;5(4):419\u201323.","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"3715_CR115","doi-asserted-by":"crossref","unstructured":"Singal AG et al. Mailed outreach invitations significantly improve HCC surveillance rates in patients with cirrhosis: a randomized clinical trial, Hepatology, vol. 69, no. 1, pp. 121\u2013130, 2019.","DOI":"10.1002\/hep.30129"},{"issue":"1","key":"3715_CR116","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13046-021-01968-w","volume":"40","author":"X-Y Luo","year":"2021","unstructured":"Luo X-Y, Wu K-M, He X-X. Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. J Experimental Clin Cancer Res. 2021;40(1):172.","journal-title":"J Experimental Clin Cancer Res"},{"key":"3715_CR117","doi-asserted-by":"crossref","unstructured":"Foerster F, Galle PR. The current landscape of clinical trials for systemic treatment of HCC, Cancers, vol. 13, no. 8, p. 1962, 2021.","DOI":"10.3390\/cancers13081962"},{"issue":"14","key":"3715_CR118","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.7150\/ijms.59930","volume":"18","author":"Y Gao","year":"2021","unstructured":"Gao Y, Lyu L, Feng Y, Li F, Hu Y. A review of cutting-edge therapies for hepatocellular carcinoma (HCC): perspectives from patents. Int J Med Sci. 2021;18(14):3066.","journal-title":"Int J Med Sci"},{"key":"3715_CR119","doi-asserted-by":"crossref","unstructured":"Jayasinghe S, Munaweera I, Dedunupitiya D, Madhusha C, Kottegoda N, Karunaratne V. Recent Patents and Commercially Available Nanotherapeutics on Hepatocellular Carcinoma, in Nanotherapeutics for the Treatment of Hepatocellular Carcinoma. Bentham Science; 2022. pp. 449\u201389.","DOI":"10.2174\/9789815039740122010013"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03715-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03715-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03715-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T01:03:23Z","timestamp":1782090203000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03715-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":119,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3715"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03715-5","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"140"}}